Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study
Objective. The aim of study was to evaluate the effect and safety of pioglitazone-metformin combined treatment in the newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease. Methods. A total of 120 newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2023/2044090 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546690109800448 |
|---|---|
| author | Fu Jianfang Xiao Wanxia Gao Xiling Xu Jing Yang Wenjuan Liu Jianrong He Qingzhen Ma Kaiyan Lian Jingxuan Chen Taixiong Xu Qian Li Mengying Ming Jie Ji Qiuhe |
| author_facet | Fu Jianfang Xiao Wanxia Gao Xiling Xu Jing Yang Wenjuan Liu Jianrong He Qingzhen Ma Kaiyan Lian Jingxuan Chen Taixiong Xu Qian Li Mengying Ming Jie Ji Qiuhe |
| author_sort | Fu Jianfang |
| collection | DOAJ |
| description | Objective. The aim of study was to evaluate the effect and safety of pioglitazone-metformin combined treatment in the newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease. Methods. A total of 120 newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease from 8 centers were randomly divided into the control group (metformin hydrochloride) and the test group (pioglitazone hydrochloride and metformin hydrochloride). Results. Compared to the control group, after treatment, the proportion of people with mild and moderate fatty liver increased, and the proportion of people with severe fatty liver decreased, and this change was more obvious in the population with moderate and severe fatty liver. The level of γ-GT decreased in both groups before and after treatment, which was statistically significant, and there was also a statistically significant difference in the level of γ-GT between the two groups after 24 weeks. There were no significant statistically differences in blood lipid, body weight, and waist circumference between the test group and the control group. Logistic regression analysis found that BMI is one of the risk factors for fatty liver. There was also no significant difference in the incidence of serious adverse events between the two groups (control group: 10.00% and test group: 6.67%, P=0.74). Conclusion. Combined treatment with pioglitazone-metformin can effectively reduce liver fat content and gamma-GT level in newly diagnosed diabetic patients with nonalcoholic fatty liver disease, and adverse events do not increase compared with the control group, showing good safety and tolerance. This trial is registered with ClinicalTrials.gov NCT03796975. |
| format | Article |
| id | doaj-art-b43ba2c77cd64fafb29e900f38a09e83 |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-b43ba2c77cd64fafb29e900f38a09e832025-02-03T06:47:31ZengWileyJournal of Diabetes Research2314-67532023-01-01202310.1155/2023/2044090Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter StudyFu Jianfang0Xiao Wanxia1Gao Xiling2Xu Jing3Yang Wenjuan4Liu Jianrong5He Qingzhen6Ma Kaiyan7Lian Jingxuan8Chen Taixiong9Xu Qian10Li Mengying11Ming Jie12Ji Qiuhe13Air Force Medical University Xijing HospitalGenertec Universal Xian Aero-Engine HospitalYan’an People’s HospitalXi’an Jiaotong University Second Affiliated HospitalShaanxi Aerospace HospitalChang’an HospitalGaoxin HospitalShangluo Central HospitalAir Force Medical University Xijing HospitalAir Force Medical University Xijing HospitalAir Force Medical University Xijing HospitalAir Force Medical University Xijing HospitalAir Force Medical University Xijing HospitalAir Force Medical University Xijing HospitalObjective. The aim of study was to evaluate the effect and safety of pioglitazone-metformin combined treatment in the newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease. Methods. A total of 120 newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease from 8 centers were randomly divided into the control group (metformin hydrochloride) and the test group (pioglitazone hydrochloride and metformin hydrochloride). Results. Compared to the control group, after treatment, the proportion of people with mild and moderate fatty liver increased, and the proportion of people with severe fatty liver decreased, and this change was more obvious in the population with moderate and severe fatty liver. The level of γ-GT decreased in both groups before and after treatment, which was statistically significant, and there was also a statistically significant difference in the level of γ-GT between the two groups after 24 weeks. There were no significant statistically differences in blood lipid, body weight, and waist circumference between the test group and the control group. Logistic regression analysis found that BMI is one of the risk factors for fatty liver. There was also no significant difference in the incidence of serious adverse events between the two groups (control group: 10.00% and test group: 6.67%, P=0.74). Conclusion. Combined treatment with pioglitazone-metformin can effectively reduce liver fat content and gamma-GT level in newly diagnosed diabetic patients with nonalcoholic fatty liver disease, and adverse events do not increase compared with the control group, showing good safety and tolerance. This trial is registered with ClinicalTrials.gov NCT03796975.http://dx.doi.org/10.1155/2023/2044090 |
| spellingShingle | Fu Jianfang Xiao Wanxia Gao Xiling Xu Jing Yang Wenjuan Liu Jianrong He Qingzhen Ma Kaiyan Lian Jingxuan Chen Taixiong Xu Qian Li Mengying Ming Jie Ji Qiuhe Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study Journal of Diabetes Research |
| title | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study |
| title_full | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study |
| title_fullStr | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study |
| title_full_unstemmed | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study |
| title_short | Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study |
| title_sort | effect and safety of pioglitazone metformin tablets in the treatment of newly diagnosed type 2 diabetes patients with nonalcoholic fatty liver disease in shaanxi province a randomized double blinded double simulated multicenter study |
| url | http://dx.doi.org/10.1155/2023/2044090 |
| work_keys_str_mv | AT fujianfang effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT xiaowanxia effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT gaoxiling effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT xujing effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT yangwenjuan effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT liujianrong effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT heqingzhen effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT makaiyan effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT lianjingxuan effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT chentaixiong effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT xuqian effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT limengying effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT mingjie effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy AT jiqiuhe effectandsafetyofpioglitazonemetformintabletsinthetreatmentofnewlydiagnosedtype2diabetespatientswithnonalcoholicfattyliverdiseaseinshaanxiprovincearandomizeddoubleblindeddoublesimulatedmulticenterstudy |